Tempus AI CFO James William Rogers Sells 11,529 Common Shares for $634,095

AI Software Shares Rise. Roblox up over 12%; AppLovin up About 5%; Palantir, TEAM up About 4%; DataDog, ServiceNow up over 3%

tempus AI Inc Class A call volume above normal and directionally bullish

Tempus AI Launches Angiosarcoma Research Collaboration with Angiosarcoma Awareness

Anthropic’S Mythos Model Uncovers US Intelligence Vulnerabilities Within Hours; Demonstrates Potent Cyber Defense And Offense Capabilities

BofA Warns: AI Bubble Flashes Historic Danger Signals

Tempus AI says multi-center study validates FDA-cleared ECG model predicting 1-year atrial fibrillation risk

Tempus unit Ambry study finds ExomeReveal RNA testing boosts clarity for uncertain exome results

Skip the Oura Ring IPO. Buy These 10 Stocks Instead.

Tempus AI director David R. Epstein reports disposal of 250 common shares worth $12,350

Tempus AI launches open-source digital pathology consortium

Tempus AI assumed with a Peer Perform at Wolfe Research

Tempus AI announced the upcoming clinical availability of xH

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, Xh

Guggenheim Reaffirms Their Buy Rating on Tempus AI, Inc. Class A (TEM)

Tempus AI Price Target Maintained With a $80.00/Share by BTIG

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM) and Incyte (INCY)